UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of July 2026

 

Commission File Number: 001-41773

 

Adlai Nortye Ltd.

 

c/o PO Box 309, Ugland House

Grand Cayman, KY1-1104

Cayman Islands

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

☒ Form 20-F       ☐ Form 40-F

 

 

 

  

 

 

Press Release

 

On July 16, 2026, Adlai Nortye Ltd. issued a press release entitled “Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025”, a copy of the press release is attached to this Form 6-K as Exhibit 99.1.

 

Exhibits 

 

Exhibit No.   Description
99.1   Press Release: Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

 

 1 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Adlai Nortye Ltd.
   
  By: /s/ Yang Lu
  Name:  Yang Lu
  Title: Chief Executive Officer and Chairman of Board of Directors

 

Date: July 16, 2026

 

 2 

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

PRESS RELEASE: ADLAI NORTYE ANNOUNCES FIRST PATIENT DOSED IN INTERMITTENT WEEKLY DOSING ARM OF GLOBAL PHASE 1 TRIAL OF PAN-RAS(ON) INHIBITOR AN9025